Sutro Biopharma (STRO) Competitors $0.76 +0.00 (+0.13%) As of 07/3/2025 02:21 PM Eastern This is a fair market value price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSustainabilityTrendsBuy This Stock STRO vs. TRDA, ALLO, TSVT, ADCT, ANNX, AMRN, INZY, SGMT, RNAC, and CRVSShould you be buying Sutro Biopharma stock or one of its competitors? The main competitors of Sutro Biopharma include Entrada Therapeutics (TRDA), Allogene Therapeutics (ALLO), 2seventy bio (TSVT), ADC Therapeutics (ADCT), Annexon (ANNX), Amarin (AMRN), Inozyme Pharma (INZY), Sagimet Biosciences (SGMT), Cartesian Therapeutics (RNAC), and Corvus Pharmaceuticals (CRVS). These companies are all part of the "pharmaceutical products" industry. Sutro Biopharma vs. Its Competitors Entrada Therapeutics Allogene Therapeutics 2seventy bio ADC Therapeutics Annexon Amarin Inozyme Pharma Sagimet Biosciences Cartesian Therapeutics Corvus Pharmaceuticals Sutro Biopharma (NASDAQ:STRO) and Entrada Therapeutics (NASDAQ:TRDA) are both small-cap medical companies, but which is the better stock? We will compare the two businesses based on the strength of their analyst recommendations, valuation, earnings, dividends, institutional ownership, media sentiment, risk and profitability. Do insiders & institutionals believe in STRO or TRDA? 97.0% of Sutro Biopharma shares are owned by institutional investors. Comparatively, 86.4% of Entrada Therapeutics shares are owned by institutional investors. 5.9% of Sutro Biopharma shares are owned by insiders. Comparatively, 7.6% of Entrada Therapeutics shares are owned by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock is poised for long-term growth. Do analysts recommend STRO or TRDA? Sutro Biopharma presently has a consensus price target of $6.11, indicating a potential upside of 699.25%. Entrada Therapeutics has a consensus price target of $25.67, indicating a potential upside of 254.76%. Given Sutro Biopharma's higher possible upside, research analysts clearly believe Sutro Biopharma is more favorable than Entrada Therapeutics.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Sutro Biopharma 1 Sell rating(s) 4 Hold rating(s) 3 Buy rating(s) 0 Strong Buy rating(s) 2.25Entrada Therapeutics 0 Sell rating(s) 0 Hold rating(s) 3 Buy rating(s) 1 Strong Buy rating(s) 3.25 Which has preferable valuation & earnings, STRO or TRDA? Entrada Therapeutics has higher revenue and earnings than Sutro Biopharma. Sutro Biopharma is trading at a lower price-to-earnings ratio than Entrada Therapeutics, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioSutro Biopharma$62.04M1.04-$227.46M-$2.98-0.26Entrada Therapeutics$210.78M1.30$65.63M$0.818.93 Does the media favor STRO or TRDA? In the previous week, Entrada Therapeutics had 14 more articles in the media than Sutro Biopharma. MarketBeat recorded 14 mentions for Entrada Therapeutics and 0 mentions for Sutro Biopharma. Entrada Therapeutics' average media sentiment score of 0.13 beat Sutro Biopharma's score of 0.00 indicating that Entrada Therapeutics is being referred to more favorably in the news media. Company Overall Sentiment Sutro Biopharma Neutral Entrada Therapeutics Neutral Is STRO or TRDA more profitable? Entrada Therapeutics has a net margin of 14.39% compared to Sutro Biopharma's net margin of -373.66%. Entrada Therapeutics' return on equity of 5.84% beat Sutro Biopharma's return on equity.Company Net Margins Return on Equity Return on Assets Sutro Biopharma-373.66% -347.60% -59.46% Entrada Therapeutics 14.39%5.84%4.61% Which has more volatility & risk, STRO or TRDA? Sutro Biopharma has a beta of 1.64, meaning that its share price is 64% more volatile than the S&P 500. Comparatively, Entrada Therapeutics has a beta of -0.11, meaning that its share price is 111% less volatile than the S&P 500. SummaryEntrada Therapeutics beats Sutro Biopharma on 13 of the 16 factors compared between the two stocks. Get Sutro Biopharma News Delivered to You Automatically Sign up to receive the latest news and ratings for STRO and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding STRO and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart STRO vs. The Competition Export to ExcelMetricSutro BiopharmaMED IndustryMedical SectorNASDAQ ExchangeMarket Cap$64.61M$2.89B$5.53B$9.02BDividend YieldN/A2.44%5.22%3.99%P/E Ratio-0.2621.7127.7020.25Price / Sales1.04283.26419.56119.26Price / CashN/A41.7026.2128.59Price / Book1.427.538.035.65Net Income-$227.46M-$55.14M$3.18B$249.15M7 Day Performance7.16%4.22%2.88%2.91%1 Month Performance-9.79%0.91%1.67%4.11%1 Year Performance-73.80%5.40%34.39%20.98% Sutro Biopharma Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)STROSutro Biopharma3.193 of 5 stars$0.77+0.1%$6.11+699.3%-73.8%$64.61M$62.04M-0.26240TRDAEntrada Therapeutics3.4947 of 5 stars$7.04-1.1%$25.67+264.6%-48.8%$267.17M$210.78M8.69110Insider TradeALLOAllogene Therapeutics2.9968 of 5 stars$1.22-0.8%$8.44+592.2%-43.9%$266.85M$20K-0.99310TSVT2seventy bioN/A$5.00flat$5.00N/A$266.15M$48.37M-2.69440ADCTADC Therapeutics1.5232 of 5 stars$2.68-3.2%$7.75+189.2%-14.4%$265.80M$70.84M-1.85310ANNXAnnexon2.2728 of 5 stars$2.38flat$12.50+425.2%-34.2%$261.12MN/A-2.0260Positive NewsAMRNAmarin0.7924 of 5 stars$12.60+0.5%$7.00-44.4%+9.9%$260.95M$228.61M-3.46360Gap UpINZYInozyme Pharma3.4113 of 5 stars$3.99flat$11.75+194.5%N/A$257.60MN/A-2.3650Analyst UpgradeSGMTSagimet Biosciences2.3974 of 5 stars$8.36-4.1%$23.17+177.1%+175.2%$256.44M$2M-4.758RNACCartesian Therapeutics1.4169 of 5 stars$9.83+0.7%$43.00+337.4%-34.1%$255.09M$38.91M-0.1964CRVSCorvus Pharmaceuticals2.4595 of 5 stars$3.73-5.8%$15.00+302.1%+116.2%$254.27MN/A-3.8130Positive News Related Companies and Tools Related Companies Entrada Therapeutics Alternatives Allogene Therapeutics Alternatives 2seventy bio Alternatives ADC Therapeutics Alternatives Annexon Alternatives Amarin Alternatives Inozyme Pharma Alternatives Sagimet Biosciences Alternatives Cartesian Therapeutics Alternatives Corvus Pharmaceuticals Alternatives Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:STRO) was last updated on 7/7/2025 by MarketBeat.com Staff From Our PartnersA grave, grave error.I thought what happened 25 years ago was a once- in-a-lifetime event… but how wrong I was. Because here we...Porter & Company | SponsoredThis Signal Only Flashes Once Every 4 Years – And It Just TriggeredThis same signal has appeared twice before in the past 8 years — both times, it kicked off major moves in cryp...Crypto Swap Profits | SponsoredBanks aren’t ready for this altcoin—are you?Our expert analysts have identified a $100 billion gap in the crypto market. Only one project is perfectly ...Crypto 101 Media | SponsoredIs Elon's empire crumbling?The Tesla Shock Nobody Sees Coming While headlines scream "Tesla is doomed"... Jeff Brown has uncovered ...Brownstone Research | SponsoredINVESTOR ALERT: Tiny “$3 AI Wonder Stock” on the Verge of Blasting OffRight now, we’re witnessing a monumental shift in the world.Traders Agency | SponsoredPresidential Bombshell: $150T Resource to Be Released as soon as this Summer?Something extraordinary is happening in Washington. For the first time in over a century, a sitting Preside...Paradigm Press | SponsoredWhite House to reset Social Security?Elon Musk's parting DOGE gift looks set to shock America... A single announcement by July 22nd could soon b...Altimetry | SponsoredMarket Panic: Trump Just Dropped a Bomb on Your Stockstock Market Panic: Trump Just Dropped a Bomb on Your Stocks The market is in freefall—and Trump's new tarif...American Alternative | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Sutro Biopharma, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Sutro Biopharma With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
